Frankfurt - Delayed Quote • EUR
United Therapeutics Corporation (UTH.F)
At close: April 26 at 8:01 AM GMT+2
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Sep 2021) | Next Qtr. (Dec 2021) | Current Year (2021) | Next Year (2022) |
|---|---|---|---|---|
| No. of Analysts | 7 | 7 | 7 | 8 |
| Avg. Estimate | 3.56 | 3.59 | 11.87 | 16.15 |
| Low Estimate | 3.12 | 3.04 | 10.47 | 11.72 |
| High Estimate | 4.26 | 4.15 | 15 | 19.7 |
| Year Ago EPS | 3.84 | 2.19 | 11.54 | 11.87 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Sep 2021) | Next Qtr. (Dec 2021) | Current Year (2021) | Next Year (2022) |
|---|---|---|---|---|
| No. of Analysts | 8 | 8 | 8 | 9 |
| Avg. Estimate | 423.64M | 425.13M | 1.67B | 1.85B |
| Low Estimate | 391.7M | 383.1M | 1.6B | 1.55B |
| High Estimate | 460.84M | 458.76M | 1.75B | 2.06B |
| Year Ago Sales | 380.1M | 384.9M | 1.48B | 1.67B |
| Sales Growth (year/est) | 11.50% | 10.50% | 12.90% | 10.30% |
Earnings History
| CURRENCY IN USD | 9/30/2020 | 12/31/2020 | 3/31/2021 | 6/30/2021 |
|---|---|---|---|---|
| EPS Est. | 2.83 | 3.14 | 2.94 | 3.02 |
| EPS Actual | 3.84 | 2.19 | 0.61 | 3.65 |
| Difference | 1.01 | -0.95 | -2.33 | 0.63 |
| Surprise % | 35.70% | -30.30% | -79.30% | 20.90% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Sep 2021) | Next Qtr. (Dec 2021) | Current Year (2021) | Next Year (2022) |
|---|---|---|---|---|
| Current Estimate | 3.56 | 3.59 | 11.87 | 16.15 |
| 7 Days Ago | 3.56 | 3.59 | 11.34 | 16.13 |
| 30 Days Ago | 3.56 | 3.59 | 11.34 | 16.27 |
| 60 Days Ago | 3.36 | 3.5 | 10.73 | 15.06 |
| 90 Days Ago | 3.32 | 3.46 | 10.76 | 15 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Sep 2021) | Next Qtr. (Dec 2021) | Current Year (2021) | Next Year (2022) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | 1 | -- |
| Up Last 30 Days | 1 | 1 | 2 | 1 |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | 1 | -- | -- | 1 |
Growth Estimates
| CURRENCY IN USD | UTH.F | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | -7.30% | -- | -- | 6.50% |
| Next Qtr. | 63.90% | -- | -- | 12.00% |
| Current Year | 2.90% | -- | -- | 5.30% |
| Next Year | 36.10% | -- | -- | 13.10% |
| Next 5 Years (per annum) | 1.50% | -- | -- | 11.09% |
| Past 5 Years (per annum) | 1.35% | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
| Maintains | Wells Fargo: Overweight to Overweight | 3/7/2024 |
| Reiterates | Wedbush: Outperform to Outperform | 2/22/2024 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 2/22/2024 |
| Upgrade | Goldman Sachs: Sell to Neutral | 2/12/2024 |
| Initiated | Leerink Partners: Outperform | 2/5/2024 |
| Maintains | JP Morgan: Overweight to Overweight | 11/2/2023 |